ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ARGENX SE

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026

$825.61+6.47 (+0.79%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 42.2
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Jul 23, 2026	Before market open	$1.54B	$7.32	–
Q4 FY2025 Ended Dec 31, 2025	Feb 26, 2026	Before market open	$1.30B	$8.02	–
Q2 FY2025 Ended Jun 30, 2025	Jul 31, 2025	Before market open	$967.00M	$3.74	–
Q4 FY2024 Ended Dec 31, 2024	Feb 27, 2025	Before market open	$761.00M	$11.79	–
Q2 FY2023 Ended Jun 30, 2023	Jul 27, 2023	Before market open	$269.00M	$-1.69	–

Company guidance

Outlook given with results on Jul 31, 2025, compared with the previous outlook

Measure	Period	Guidance	vs. prior
combined research and development and selling, general and administrative	2025	$2.50B	Maintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Argenx filed with the SEC

Oct 8, 2026, 6:01 AM ET
argenx Announces Positive Topline Results from
EX-99.1 to Form 6-K
Oct 8, 2026, 6:01 AM ET
argenx Provides Update on Phase 3 UNITY Study
EX-99.2 to Form 6-K
Sep 29, 2026, 8:38 AM ET
argenx Presents New Data at AANEM and MGFA Scientific
EX-99.1 to Form 6-K
Aug 27, 2026, 4:19 PM ET
argenx Completes Acquisition of Forte Biosciences, Inc.
EX-99.1 to Form 6-K
Aug 17, 2026, 8:54 AM ET
argenx Announces Positive Topline Results from
EX-99.1 to Form 6-K
Aug 17, 2026, 8:54 AM ET
This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation
EX-99.2 to Form 6-K
Aug 3, 2026, 4:12 PM ET
announces Extraordinary General Meeting of Shareholders on September 17, 2026
EX-99.1 to Form 6-K
Jul 27, 2026, 6:03 AM ET
argenx to Acquire Forte Biosciences, Inc., Adding
EX-99.1 to Form 6-K
Jul 23, 2026, 8:21 AM ET
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
EX-99.1 to Form 6-K
Jul 23, 2026, 8:21 AM ET
argenx Half-Year 2026 Financial Report
EX-99.2 to Form 6-K
Jul 23, 2026, 8:21 AM ET
VISION 2030 is our Engine for Long-term Growth 50k 10 5 patients on treatment labeled indications late-stage molecules Scale VYVGART in MG and CIDP Expand across indications and assets Build diversified immunology portfolio in FcRn and beyond 3
EX-99.3 to Form 6-K
Jun 23, 2026, 6:22 AM ET
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology
EX-99.1 to Form 6-K
Jun 3, 2026, 7:16 AM ET
argenx Presents New Efgartigimod Data Showing
EX-99.1 to Form 6-K
May 8, 2026, 9:08 PM ET
argenx Announces U.S. FDA Approval Expanding
EX-99.1 to Form 6-K
May 7, 2026, 8:46 AM ET
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
EX-99.1 to Form 6-K
May 7, 2026, 8:46 AM ET
VISION 2030 5 New Molecules in Phase 310 Labeled Indications50K Patients on Treatment Commitment To Our Transformation Mission Continuous Pipeline of InnovationLeadership in FcRnDisciplined Scaling 3
EX-99.2 to Form 6-K
May 6, 2026, 4:28 PM ET
of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
EX-99.1 to Form 6-K
Apr 20, 2026, 6:02 AM ET
argenx Brings Neuromuscular Leadership to AAN
EX-99.1 to Form 6-K
Mar 20, 2026, 4:24 PM ET
announces Annual General Meeting of Shareholders on May 6, 2026
EX-99.1 to Form 6-K
Mar 19, 2026, 6:05 AM ET
To our Shareholders Shareholder Letter 10 2025 In Brief 11 2026 Outlook 17 argenx Annual Report 2025 9
EX-99.1 to Form 6-K
Mar 6, 2026, 6:15 AM ET
argenx to Present New Data at 2026 AAN Annual
EX-99.1 to Form 6-K
Feb 26, 2026, 8:37 AM ET
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
EX-99.1 to Form 6-K
Feb 26, 2026, 8:37 AM ET
UNAUDITED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
EX-99.2 to Form 6-K
Feb 26, 2026, 8:37 AM ET
Advancing Vision 2030 10 New Molecules Entered Pipeline 4 Ongoing Registrational Studies ~19K Patients Treated Globally* 5 10 50 New Molecules in Phase 3 Patients on TreatmentK Labeled Indications VISION 2030 Michele, CIDP Patient Execution in 2025
EX-99.3 to Form 6-K
Feb 26, 2026, 6:20 AM ET
argenx Announces Positive Topline Results from
EX-99.1 to Form 6-K
Jan 13, 2026, 6:05 AM ET
argenx Announces FDA Acceptance of Supplemental
EX-99.1 to Form 6-K
Jan 12, 2026, 4:05 PM ET
billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales
EX-99.1 to Form 6-K
Jan 12, 2026, 4:05 PM ET
Leading a new era of innovation in immunology
EX-99.2 to Form 6-K
Jan 5, 2026, 7:26 AM ET
argenx Announces Leadership Transition Marking
EX-99.1 to Form 6-K
Dec 15, 2025, 6:15 AM ET
argenx Provides Update on UplighTED Studies
EX-99.1 to Form 6-K
Nov 18, 2025, 5:01 PM ET
Extraordinary General Meeting of Shareholders
EX-99.1 to Form 6-K
Oct 30, 2025, 8:04 AM ET
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
EX-99.1 to Form 6-K
Oct 30, 2025, 8:04 AM ET
Fuel pipeline growth 2025 Strategic Priorities PFS Launch Expand next wave of innovation 4 New Molecules in Phase 1 3 Reach more patients with VYVGART 10 Phase 3s 10 Phase 2s 3
EX-99.2 to Form 6-K
Oct 29, 2025, 11:11 AM ET
argenx Presents New Data at AANEM and MGFA Highlighting
EX-99.1 to Form 6-K
Oct 15, 2025, 6:05 AM ET
argenx to Highlight Key Data and Breadth of
EX-99.1 to Form 6-K
Oct 3, 2025, 4:32 PM ET
announces Extraordinary General Meeting of Shareholders on November 18, 2025
EX-99.1 to Form 6-K
Aug 25, 2025, 7:23 AM ET
argenx Announces Positive Topline Results from
EX-99.1 to Form 6-K
Jul 31, 2025, 8:16 AM ET
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
EX-99.1 to Form 6-K
Jul 31, 2025, 8:16 AM ET
argenx Half-Year 2025 Financial Report
EX-99.2 to Form 6-K
Jul 31, 2025, 8:16 AM ET
Advancing a Late-Stage Pipeline with Transformative Potential Efgartigimod Empasiprubart ARGX-119 indications Potent C2 sweeping antibody MuSK agonist antibody First and only Fc Fragment Ongoing registrational studies Ongoing registrational studies indications indications Registrational study to …
EX-99.3 to Form 6-K